Inspire Medical Systems, Inc. (NYSE: INSP) is currently under scrutiny as a class action lawsuit has been filed against the company, focusing on significant allegations of misleading statements and undisclosed operational challenges. The lawsuit is aimed at protecting investors who acquired Inspire securities during a specific period from August 6, 2024, through August 4, 2025.

2. Allegations Against Inspire Medical

The key allegations in the lawsuit highlight a series of failures related to the launch of Inspire’s latest product, Inspire V, an implantable medical device aimed at treating obstructive sleep apnea. According to the complaint, the defendants within the company made false and/or misleading statements and failed to disclose critical issues that were affecting the product's market performance.

Key points of the allegations include:

Poor Demand for Inspire V: The lawsuit claims that demand for the device was weak, with medical providers reportedly holding significant amounts of surplus inventory. This reluctance to transition to the new treatment suggests that the rollout was not as successful as the company had purported.

Inadequate Preparation for Launch: Despite assurances from the company that all necessary steps had been taken for a successful launch, the lawsuit contends that Inspire Medical failed to complete essential tasks. These tasks were crucial for the effective introduction of Inspire V into the market.

3. Impact of Recent Company Developments

On August 4, 2025, Inspire Medical made a troubling announcement regarding the Inspire V launch. The company indicated that the rollout was facing an "elongated timeframe," attributed to many treatment centers not completing the required training, contracting, and onboarding criteria necessary for the purchase and implantation of Inspire V.

Additionally, the company's update revealed that software updates required for claims submissions and processing would not take effect until July 1, 2025. This delay hindered implanting centers from billing for procedures, compelling many to continue using an earlier version of the Inspire device instead.

The repercussions of these developments were severe. Following the announcement, Inspire Medical's stock price dropped dramatically, falling by $42.04 or approximately 32.35%, from $129.95 per share on August 4, closing at $87.91 on August 5, 2025. This drastic decline reflects the market's reaction to the disappointing news regarding the product launch and the company's reduced earnings guidance for 2025, which was slashed by over 80%.

4. Class Action Details

The law firm Kirby McInerney LLP is leading the charge for the class action, reminding investors of the January 5, 2026, deadline to seek lead plaintiff appointment. The firm emphasizes the importance of this lawsuit for shareholders who may have suffered losses due to Inspire's alleged missteps.

5. What Affected Investors Should Know

Investors who purchased or otherwise acquired Inspire securities during the specified class period are encouraged to reach out to Kirby McInerney LLP to discuss their rights and interests. The firm has a notable history in securities litigation, having achieved recoveries totaling billions of dollars for shareholders.

Conclusion

The unfolding events surrounding Inspire Medical Systems underscore the volatility and risks associated with emerging medical technologies. As the company navigates this challenging period, investors are left to grapple with the implications of the ongoing class action lawsuit and the impact it may have on Inspire’s future operations and stock performance.

Original press release